¿ä·Î»ý½Ä±â°¨¿° Á¦2ÆÇ (Urogenital tract infection and inflammation)
- ÀúÀÚ(±Û)ÀÌÁ¤¿ì ¿Ü
- ÃâÆÇ»ç±ºÀÚÃâÆÇ»ç
- ¹ßÇàÀÏ2022³â 04¿ù 29ÀÏ
·Îº¿ ¼ö¼ú·Î Àü¸³¼±¾Ï Ä¡·áÀÇ »õ ÁöÆò ¿´Ù
Àü¸³¼± Áúȯ°ú ºñ´¢±â Á¾¾ç ºÐ¾ßÀÇ ±ÇÀ§ÀÚ·Î ¼Õ²ÅÈ÷´Â ÀÌÁ¤¿ì ±³¼ö´Â ÃֽŠ·Îº¿ ¼ö¼ú ±â¹ýÀ» µµÀÔÇÏ¿© Àü¸³¼±¾Ï Ä¡·á¿¡¼ Ź¿ùÇÑ ¼º°ú¸¦ º¸À̰í ÀÖ´Ù. ȯÀÚ ¸ÂÃãÇü Ä¡·á °èȹ ¼ö¸³¿¡ ÁÖ·ÂÇϰí ÀÖÀ¸¸ç, ´ÙÇÐÁ¦Àû Á¢±ÙÀ» ÅëÇØ º¹ÀâÇÑ ºñ´¢±â Áúȯ¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ Ä¡·á Àü·«À» ¼ö¸³ÇÏ´Â µ¥ ±â¿©Çϰí ÀÖ´Ù. ±¹³»¿Ü Çмú Ȱµ¿À» ÅëÇØ ºñ´¢ÀÇÇÐ ¹ßÀüÀ» ¼±µµÇϰí ÀÖÀ¸¸ç, ƯÈ÷ Àü¸³¼±¾Ï Á¶±â Áø´Ü ¹× Ä¡·á ¿¬±¸·Î ÁÖ¸ñ¹Þ°í ÀÖ´Ù.
| Á¦ ¸ñ | Àü¸³¼±¾Ï Ä¡·á Áø·á±Ç°í¾È | ||
|---|---|---|---|
| ÃâÆÇ»ç | ¹ßÇàÀÏ | 2018³â 01¿ù | |
| Á¦ ¸ñ | Prevalence of bladder pain syndrome-like symptoms: a population-based study in Korea | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2021 | ¹ßÇ¥Áö | |
| Á¦ ¸ñ | Clinical and microbiological characteristics of men with nonobstructive acute pyelonephritis: a multicenter retrospective observational study | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2021 | ¹ßÇ¥Áö | |
| Á¦ ¸ñ | Characteristics and treatment trends for emphysematous pyelonephritis in Korea: a 10-year multicenter retrospective study | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2021 | ¹ßÇ¥Áö | |
| Á¦ ¸ñ | Spontaneous rupture of adrenal myelolipoma as a cause of acute flank pain: a case report | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2021 | ¹ßÇ¥Áö | |
| Á¦ ¸ñ | Platelet-to-lymphocyte ratio is not a predictor of clinically significant prostate cancer at the prostate biopsy: a large cohort study | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2021 | ¹ßÇ¥Áö | |
| Á¦ ¸ñ | Diabetes mellitus promotes smooth muscle cell proliferation in mouse ureteral tissue through the P-ERK/P-LNK/VEGF/PKC signaling pathway | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2021 | ¹ßÇ¥Áö | |
| Á¦ ¸ñ | Microbiological features and clinical factors associated with empirical antibiotic resistance in febrile patients with upper urinary tract calculi | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2021 | ¹ßÇ¥Áö | |

°æÈñ´ëÇб³º´¿øÀº ȯÀÚ Áß½ÉÀÇ ÀÇ·á ¼ºñ½º¸¦ Á¦°øÇϸç, ±¹³» ÀÇ·á°è¸¦ ¼±µµÇÏ´Â »ó±ÞÁ¾ÇÕº´¿øÀÔ´Ï´Ù. ÃֽŠÀÇ·á ±â¼ú°ú Àåºñ¸¦ Ȱ¿ëÇÏ¿© ȯÀڵ鿡°Ô ÃÖ»óÀÇ Ä¡·á¸¦ Á¦°øÇÕ´Ï´Ù. ƯÈ÷ ÁßÁõÁúȯ Ä¡·á ¹× ¿¬±¸¿¡ °Á¡À» º¸À̸ç, ´ÙÇÐÁ¦ ÇùÁø ½Ã½ºÅÛÀ» ÅëÇØ ȯÀÚÀÇ °Ç°À» ÃÖ¿ì¼±À¸·Î »ý°¢ÇÕ´Ï´Ù. °æÈñ´ëÇб³º´¿øÀº ȯÀÚµéÀÇ ½Å·Ú¿Í ¸¸Á·µµ¸¦ ³ôÀÌ´Â µ¥ ÁÖ·ÂÇϸç, Áö¼ÓÀûÀ¸·Î ÀÇ·á ǰÁú Çâ»ó°ú ¿¬±¸ °³¹ß¿¡ Èû¾²°í ÀÖ½À´Ï´Ù.
¼¿ïƯº°½Ã µ¿´ë¹®±¸ °æÈñ´ë·Î 23 °æÈñ´ëÇб³º´¿ø